UMN-03
Muscular Diseases
- Product Status
-
- Discovery
- Pre-Clinical
- PhaseⅠ
- PhaseⅡ
UMN-03 is a fusion protein being developed for myogenic and neurogenic diseases with a novel mode of action which was discovered at the University of Tokushima. The target of this biological drug candidate is so-called myostatin. Substantial published data indicate that blocking the action of myostatin can promote extra muscle growth, thus providing potential therapeutic advantage for patients with congenital intractable myopathy such as Duchenne muscular dystrophy(DMD). Furthermore, UMN-03 can reduce fat tissue and could thereby provide a new therapeutic approach for type II diabetes or obesity. We are currently negotiating with several pharmaceutical companies both domestically and internationally.